Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)

被引：0
|
作者：
Beitzen-Heineke, Antonia [1 ,2 ,3 ]
Ben Batalla, Isabel [1 ,2 ,3 ]
Berenbrok, Nikolaus [1 ,2 ,3 ]
Paesler, Sarina [1 ,2 ,3 ]
Gensch, Victoria [1 ,2 ,3 ]
von Amsberg, Gunhild [1 ,2 ]
Schafhausen, Philippe [1 ,2 ]
Riecken, Kristoffer [4 ]
Fischer, Thomas [5 ]
Pantel, Klaus [3 ]
Bokemeyer, Carsten [1 ,2 ]
Loges, Sonja [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Univ Comprehens Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Dept Hematol & Oncol,Sect BMT, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Univ Comprehens Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Dept Hematol & Oncol,Sect Pneumol, Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Ctr Med Expt, Inst Tumor Biol, Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Res Dept Cell & Gene Therapy, Dept Stem Cell Transplantat, Hamburg, Germany
[5] Otto Von Guericke Univ, Dept Hematol & Oncol, Magdeburg, Germany
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-118175
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3063
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders
    Reiter, Andreas
    Walz, Christoph
    Cross, Nicholas C. P.
    CURRENT DRUG TARGETS, 2007, 8 (02) : 205 - 216
  • [12] Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms
    Doehner, K.
    Stegelmann, F.
    Schlenk, R. F.
    Griesshammer, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (42) : 2171 - 2178
  • [13] Microarray analysis reveals distinct immune signatures in BCR-ABL positive and negative myeloproliferative neoplasms
    Ross, Cecil
    Sharma, Mugdha
    Paul, John
    Srivastava, Sweta
    INDIAN JOURNAL OF CANCER, 2023, 60 (01) : 24 - 31
  • [14] Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients
    Wille, Kai
    Huenerbein, Karlo
    Jagenberg, Ellen
    Sadjadian, Parvis
    Becker, Tatjana
    Kolatzki, Vera
    Meixner, Raphael
    Marchi, Hannah
    Fuchs, Christiane
    Griesshammer, Martin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 108 (02) : 154 - 162
  • [15] Recent advances in the bcr-abl negative chronic myeloproliferative diseases
    Michael Bennett
    David F Stroncek
    Journal of Translational Medicine, 4
  • [16] Recent advances in the bcr-abl negative chronic myeloproliferative diseases
    Bennett, Michael
    Stroncek, David F.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)
  • [17] Can Activation Induced Cytidine Deaminase Lead to Genetic Instability in Bcr-Abl Negative Myeloproliferative Neoplasms?
    Dermenci, Hasan
    Daglar, Aynur
    Akadam, Basak Peker
    Hancer, Veysel Sabri
    Gelmez, Yusuf
    Aktan, Melih
    Nalcaci, Meliha
    Yavuz, Akif S.
    BLOOD, 2012, 120 (21)
  • [18] VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms
    Gadomska, Grazyna
    Stankowska, Katarzyna
    Boinska, Joanna
    Slusarz, Robert
    Tylicka, Marzena
    Michalska, Malgorzata
    Jachalska, Anna
    Rosc, Danuta
    MEDICINA-LITHUANIA, 2017, 53 (01): : 34 - 39
  • [19] CLINICAL IMPORTANCE OF B2 GLYCOPROTEIN I ANTIBODIES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
    Kocak, M. Z.
    Dagli, M.
    Kutlucan, A.
    Basturk, A.
    Unlu, A.
    Acar, H.
    Kutlucan, L.
    HAEMATOLOGICA, 2016, 101 : 811 - 811
  • [20] DYY Risk of bleeding complications in bcr-abl negative myeloproliferative neoplams (MPN): a retrospective single center study including 852 MPN patients
    Wille, K.
    Huenerbein, K.
    Jagenberg, E.
    Sadjadian, P.
    Becker, T.
    Kolatzki, V
    Griesshammer, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 159 - 160
12345